Corcept Therapeutics Inc
CORT
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.97B
Close$
$85.22
22.9% downside
Current Fair Value
22.9% downsideOvervalued by 22.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.97 Billion |
|---|---|
| Enterprise Value | $11.89 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.95 |
| Beta | 0.46 |
| Outstanding Shares | 105,377,000 |
Return
| Return on Equity | 7.73% |
|---|---|
| Return on Assets | 6.14% |
| Return on Invested Capital | 2.92% |
Valuation & Multiples
| P/E Ratio | 213.02 |
|---|---|
| PEG | 979.12 |
| Price to Sales | 15.79 |
| Price to Book Ratio | 18.42 |
| Enterprise Value to Revenue | 14.31 |
| Enterprise Value to EBIT | 553.36 |
| Enterprise Value to Net Income | 217 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$219.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.65
Average shareholder expectationRevenue Estimate
$320.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9462▼ 113.11% |
|---|---|
| Total Calls | 50,624▼ 95.07% |
| Total Puts | 47,900▼ 97.76% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.62%▼ 51.98% |
|---|---|
| Total Invested | $2.23B▼ 30.31% |
| Investors Holding | 194▼ 175.00% |
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...